According to Renub Research latest report “China Oncology Drugs Market, Size, Forecast 2022-2027, Industry Trends, Growth, Impact of COVID-19, Opportunity Company Analysis” China Cancer Drug Market is estimated to reach US$ 35.24 Billion by 2027. An estimated 9.6 million people died from cancer in 2018, making it the second highest cause of death worldwide. Approximately 1 in 6 deaths worldwide are attributed to cancer, according to figures released by the WHO. China, the most populated nation in the world, is experiencing a marked increase in cancer rates. According to the Global Cancer Observatory 2018, China has 4,285,033 new cancer cases yearly. After regulatory measures to streamline and encourage drug development, which also opened the way for increased investment by foreign pharmaceutical firms, China seems destined to become a major developer of cancer treatments within a few years.
China cancer drug market will grow significantly with 6.84% CAGR during the forecast period 2022 to 2027:
The growth of China cancer drug market is driven by rise in the incidence of various cancer conditions, an increase in the popularity of advanced therapies, ageing population, increased R&D investment, changing sedentary lifestyle, and westernized diet. Additionally, increased cancer awareness and cancer drug availability are anticipated to boost market expansion. Furthermore, an increase in pipeline products is expected to provide new prospects for market participants in the future.
Request a Free Sample Copy of the Report: https://www.renub.com/request-sample-page.php?gturl=china-cancer-drugs-market-p.php
Targeted Therapy dominates the Market:
Based on therapy, China cancer drug market is divided into Chemotherapy, Targeted Therapy, Immunotherapy, and Hormonal therapy. Targeted therapy holds the largest market share since targeted medicines have higher efficacy and survival rates as they can only eliminate malignant cells. Furthermore, Immunotherapy will also grow during the forecast period since immunotherapy medications may be harmless to the body’s other living cells, making them less toxic than other cancer treatments.
Therapy
1. Chemotherapy
2. Targeted Therapy
3. Immunotherapy (Biologic Therapy)
4. Hormonal Therapy
Indication
1. Blood Cancer
2. Breast Cancer
3. Gastrointestinal Cancer
4. Prostate Cancer
5. Lung Cancer
6. Skin Cancer
7. Ovarian Cancer
8. Cervical Cancer
9. Kidney Cancer
10. Other Cancers
Drugs
1. ESAs (Erythropoiesis Stimulating Agents)
2. G-CSFs (Granulocyte-colony Stimulating Factors)
3. Anti-emetics
4. Bisphosphonates
5. Opioids
6. NSAIDs & Others
Key Players
1. Bristol Myers Squibb
2. Merck
3. Eli Lilly
4. Sino BioPharma
5. F Hoffmann-La Roche AG
6. Johnson & Johnson
7. Abbvie Inc.
8. AstraZeneca plc
